Telix Announces That The Fda Has Granted Orphan Drug Designation For Tlx66 (90Y-Besilesomab), For Conditioning Treatment Prior To Hematopoietic Stem Cell Transplant (Hsct).Telix Is Pleased To Announce That The United States Food And Drug Administration (Fda) Has Granted Orphan Drug Designation (Odd) For Tlx66 (90Y-Besilesomab), For Conditioning Treatment Prior To Hematopoietic Stem Cell Transplant (Hsct).The Granting Of An Odd For Tlx66 Qualifies Telix For Various Drug Development Incentives, Which May Include Fda Administered Market Exclusivity For Seven Years, Waived Fda Prescription Drug User Fees, And Tax Credits For R&D And Clinical Development Costs.Bone Marrow Conditioning Is Performed Prior To Hsct, A Procedure Where The Patient
